ReFacto
3082A-101711
Approved small_molecule terminated
Quick answer
ReFacto for Hemophilia A is a Approved program (small_molecule) at Wyeth is now a wholly owned subsidiary of Pfizer with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Wyeth is now a wholly owned subsidiary of Pfizer
- Indication
- Hemophilia A
- Phase
- Approved
- Modality
- small_molecule
- Status
- terminated